FR11C0036I2 - Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre - Google Patents

Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre

Info

Publication number: FR11C0036I2
Authority: FR; France
Prior art keywords: pharmaceutical compositions; compositions containing; receptor agonist; sugar alcohol; solid pharmaceutical
Prior art date: 2003-04-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR11C0036C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Tanabe Seiyaku Co Ltd

Original Assignee

Novartis AG

Tanabe Seiyaku Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-08

Filing date

2011-09-08

Publication date

2023-12-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR11C0036(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-09-08 Application filed by Novartis AG, Tanabe Seiyaku Co Ltd filed Critical Novartis AG

2011-10-14 Publication of FR11C0036I1 publication Critical patent/FR11C0036I1/fr

2023-12-29 Application granted granted Critical

2023-12-29 Publication of FR11C0036I2 publication Critical patent/FR11C0036I2/fr

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Emergency Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Oil, Petroleum & Natural Gas (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Surgery (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Transplantation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

FR11C0036C 2003-04-08 2011-09-08 Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre Active FR11C0036I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US46121503P	2003-04-08	2003-04-08
PCT/EP2004/003656 WO2004089341A1 (fr)	2003-04-08	2004-04-06	Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre

Publications (2)

Publication Number	Publication Date
FR11C0036I1 FR11C0036I1 (fr)	2011-10-14
FR11C0036I2 true FR11C0036I2 (fr)	2023-12-29

Family

ID=32326722

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
FR0450692A Expired - Lifetime FR2854073B1 (fr)	2003-04-08	2004-04-06	Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre
FR11C0036C Active FR11C0036I2 (fr)	2003-04-08	2011-09-08	Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
FR0450692A Expired - Lifetime FR2854073B1 (fr)	2003-04-08	2004-04-06	Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre

Country Status (42)

Country	Link
US (11)	US20060275357A1 (fr)
EP (5)	EP2319502A1 (fr)
JP (3)	JP5495467B2 (fr)
KR (3)	KR101367574B1 (fr)
CN (2)	CN101797241B (fr)
AR (3)	AR043987A1 (fr)
AT (3)	ATE414508T1 (fr)
AU (1)	AU2004228929B2 (fr)
BE (2)	BE1015972A5 (fr)
BR (1)	BRPI0409250B8 (fr)
CA (2)	CA2707750A1 (fr)
CL (2)	CL2004000745A1 (fr)
CY (3)	CY1110260T1 (fr)
DE (4)	DE122011100047I1 (fr)
DK (2)	DK2316431T3 (fr)
EC (1)	ECSP056090A (fr)
ES (3)	ES2320767T3 (fr)
FR (2)	FR2854073B1 (fr)
GB (1)	GB2400318B (fr)
GR (1)	GR1005052B (fr)
HK (3)	HK1071685A1 (fr)
HR (3)	HRP20050886B1 (fr)
HU (2)	HUE028247T2 (fr)
IL (3)	IL170888A (fr)
IS (2)	IS2682B (fr)
IT (1)	ITMI20040682A1 (fr)
LU (1)	LU91867I2 (fr)
MA (1)	MA27729A1 (fr)
MX (1)	MXPA05010860A (fr)
MY (1)	MY141249A (fr)
NO (4)	NO329332B1 (fr)
NZ (3)	NZ592339A (fr)
PE (5)	PE20050396A1 (fr)
PL (2)	PL2316431T3 (fr)
PT (1)	PT1613288E (fr)
RU (5)	RU2358716C2 (fr)
SG (1)	SG175449A1 (fr)
SI (2)	SI2316431T1 (fr)
TN (1)	TNSN05256A1 (fr)
TW (1)	TWI332847B (fr)
WO (1)	WO2004089341A1 (fr)
ZA (1)	ZA200507394B (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0513935A (pt) *	2004-07-30	2008-05-20	Novartis Ag	formulações de compostos de 2-amina-1,3-propanodiol
CN1891212B (zh) *	2005-07-07	2010-10-13	马启明	一种口服制剂及其制备方法
ES2529724T3 (es) *	2005-09-09	2015-02-25	Novartis Ag	Tratamiento de enfermedades autoinmunes
PT2623113T (pt)	2005-11-09	2017-07-14	Onyx Therapeutics Inc	Compostos para inibição de enzimas
TWI389683B (zh) *	2006-02-06	2013-03-21	Kyorin Seiyaku Kk	A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
MY147832A (en)	2006-06-19	2013-01-31	Onyx Therapeutics Inc	Compounds for enzyme inhibition
GB0612721D0 (en)	2006-06-27	2006-08-09	Novartis Ag	Organic compounds
KR20090057399A (ko) *	2006-09-26	2009-06-05	노파르티스 아게	Ｓ１ｐ 조정제를 포함하는 제약 조성물
EP1923054A1 (fr) *	2006-09-26	2008-05-21	Novartis AG	Composition pharmaceutique à désintégration rapide comprenant un agoniste ou modulateur de S1P
EP1905434A1 (fr) *	2006-09-26	2008-04-02	Novartis AG	Compositions organiques comprenant d'un agoniste de S1P recepteur et leur utilisation therapeutique
EP1923055A1 (fr) *	2006-09-26	2008-05-21	Novartis AG	Composition pharmaceutique lyophilisée comprenant un agoniste ou modulateur de S1P
AU2011235934A1 (en) *	2006-09-26	2011-11-03	Novartis Ag	Pharmaceutical compositions comprising an S1P modulator
EP1923058A1 (fr) *	2006-09-26	2008-05-21	Novartis AG	Composition pharmaceutique enrobée comprenant un agoniste ou un modulateur de S1P
WO2008124210A1 (fr) *	2007-02-14	2008-10-16	Emory University	Procédés et compositions destinés à traiter ou prévenir une infection en utilisant des agents de séquestration des leucocytes
MY149356A (en)	2007-03-29	2013-08-30	Daiichi Sankyo Co Ltd	Pharmaceutical composition
JP5734656B2 (ja)	2007-10-04	2015-06-17	オニキスセラピューティクス，インク．ＯｎｙｘＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	ペプチドエポキシケトンプロテアーゼ阻害剤結晶及びアミノ酸ケトエポキシドの調製
AU2012216630B2 (en) *	2007-10-12	2015-01-22	Novartis Ag	Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
PL2465492T3 (pl) *	2007-10-12	2015-11-30	Novartis Ag	Mieszaniny zawierające modulatory receptora 1-fosforanu sfingozyny (S1P)
JP5534645B2 (ja) *	2008-01-11	2014-07-02	日医工株式会社	無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
WO2009099174A1 (fr)	2008-02-07	2009-08-13	Kyorin Pharmaceutical Co., Ltd.	Agent thérapeutique ou agent préventif pour maladie inflammatoire des intestins contenant un dérivé d'alcool aminé comme composant actif
KR101718639B1 (ko)	2008-03-17	2017-03-21	액테리온 파마슈티칼 리미티드	선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
KR20170081755A (ko)	2008-06-20	2017-07-12	노파르티스 아게	다발성 경화증을 치료하기 위한 소아용 조성물
BRPI0914164B1 (pt) *	2008-06-20	2019-04-30	Merck Patent Gmbh	Comistura para produção de comprimidos de desintegração rápida em um processo de formação de comprimido direto, seus usos, e formulações de comprimido
WO2010025796A1 (fr) *	2008-09-04	2010-03-11	Cargill Incorporated	Compression de l'érythritol
AU2009308516B2 (en)	2008-10-21	2016-08-25	Onyx Therapeutics, Inc.	Combination therapy with peptide epoxyketones
EP2358660A2 (fr)	2008-11-11	2011-08-24	Novartis AG	Sels de fingolimod
AU2013100532B4 (en) *	2008-11-11	2013-11-28	Novartis Ag	Crystalline forms of fingolimod HCL
RU2015111229A (ru) *	2008-11-11	2015-11-20	Новартис Аг	Кристаллические формы гидрохлорида финголимода
JP5305421B2 (ja)	2008-12-17	2013-10-02	第一三共株式会社	ジアミン誘導体の製造方法
WO2010082531A1 (fr)	2009-01-13	2010-07-22	第一三共株式会社	Inhibiteur d'un facteur actif de la coagulation sanguine
EP2407457B1 (fr)	2009-03-10	2015-04-22	Daiichi Sankyo Company, Limited	Procédé de production d'un dérivé de diamine
ES2542237T3 (es)	2009-03-13	2015-08-03	Daiichi Sankyo Company, Limited	Procedimiento de producción de un derivado de diamina ópticamente activo
TWI504598B (zh)	2009-03-20	2015-10-21	Onyx Therapeutics Inc	結晶性三肽環氧酮蛋白酶抑制劑
JPWO2010147169A1 (ja) *	2009-06-18	2012-12-06	第一三共株式会社	溶出性の改善された医薬組成物
US9675566B2 (en)	2009-07-16	2017-06-13	Pathologica Llc	Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
US8853147B2 (en)	2009-11-13	2014-10-07	Onyx Therapeutics, Inc.	Use of peptide epoxyketones for metastasis suppression
MA34133B1 (fr)	2010-03-01	2013-04-03	Onyx Therapeutics Inc	Composes pour inhibiteurs de l'immunoproteasome
CA2793413C (fr)	2010-03-19	2015-11-24	Daiichi Sankyo Company, Limited	Forme cristalline d'edoxaban tosylate monohydrate et son procede de fabrication
ES2601884T3 (es)	2010-03-19	2017-02-16	Daiichi Sankyo Company, Limited	Procedimiento para mejorar la capacidad de disolución de un anticoagulante
US20130095177A1 (en) *	2010-04-22	2013-04-18	Ratiopharm Gmbh	Method of preparing an oral dosage form comprising fingolimod
HUE031961T2 (en)	2010-07-02	2017-09-28	Daiichi Sankyo Co Ltd	A method for preparing an optically active salt of diamine derivative
EP2646409A4 (fr)	2010-11-25	2015-12-16	Shilpa Medicare Ltd	Polymorphes du fingolimode et leurs procédés
UA114283C2 (uk)	2011-01-07	2017-05-25	Новартіс Аг	Композиції імуносупресантів
DK2665471T3 (en)	2011-01-19	2018-03-19	Pathologica Llc	ORAL PHARMACEUTICAL DOSAGE FORMS WITH MANAGED RELEASE COMPREHENSIVE MGBG
JO3177B1 (ar)	2011-04-01	2018-03-08	Novartis Ag	تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
EP2739272A1 (fr)	2011-08-01	2014-06-11	Teva Pharmaceutical Industries Ltd.	Procédé de préparation de compositions pharmaceutiques comprenant du fingolimod
CN103732227B (zh)	2011-08-10	2017-04-12	第一三共株式会社	含有二胺衍生物的药物组合物
WO2013091704A1 (fr)	2011-12-22	2013-06-27	Synthon Bv	Composition pharmaceutique comprenant le fingolimod
RU2482842C1 (ru) *	2012-04-26	2013-05-27	Открытое акционерное общество "Новосибхимфарм"	Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) *	2012-06-13	2014-02-20	Открытое акционерное общество "Новосибхимфарм"	Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
EP2869820A4 (fr)	2012-07-09	2016-02-17	Onyx Therapeutics Inc	Promédicaments d'inhibiteurs d'époxy cétone protéase peptidique
RU2496486C1 (ru) *	2012-07-11	2013-10-27	Александр Васильевич Иващенко	Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
CN105163730B (zh)	2013-01-08	2018-10-30	帕萨罗杰卡有限公司	用于治疗脱髓鞘疾病的方法和组合物
WO2014141298A2 (fr) *	2013-03-11	2014-09-18	Astron Research Limited	Composition pharmaceutique stable de fingolimod
EP2990055B1 (fr) *	2013-04-26	2019-06-05	Kyoto University	Composition comprenant un agoniste du récepteur 1 de la sphingosine-1-phosphate pour empêcher la formation et/ou l'expansion d'un anévrisme cérébral ou pour réduire un tel anévrisme
ES2770500T3 (es) *	2013-05-13	2020-07-01	Synthon Bv	Composición farmacéutica que comprende fingolimod
EP3027174B1 (fr)	2013-07-29	2019-07-24	Aizant Drug Research Solutions Private Limited	Compositions pharmaceutiques à base de fingolimod
RU2530626C1 (ru) *	2013-10-21	2014-10-10	Ооо "Валента-Интеллект"	Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN106794159A (zh) *	2014-08-22	2017-05-31	广东东阳光药业有限公司	一种芬戈莫德固体组合物及其制备方法
WO2016042493A1 (fr) *	2014-09-19	2016-03-24	Aizant Drug Research Pvt. Ltd	Compositions pharmaceutiques de fingolimod
US9925138B2 (en)	2015-01-20	2018-03-27	Handa Pharmaceuticals, Llc	Stable solid fingolimod dosage forms
AU2016209466A1 (en) *	2015-01-20	2017-08-10	Handa Pharmaceuticals, Llc	Stable solid fingolimod dosage forms
US20180042895A1 (en)	2015-02-26	2018-02-15	Novartis Ag	Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) *	2015-04-09	2016-03-10	Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус"	Способ получения капсул финголимода гидрохлорида
US9690975B2 (en)	2015-05-28	2017-06-27	Axogen Corporation	Quantitative structural assay of a nerve graft
US11434200B2 (en)	2017-03-09	2022-09-06	Novartis Ag	Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
WO2018178744A1 (fr)	2017-03-29	2018-10-04	Deva Holding Anonim Sirketi	Formulations stables de fingolimod
GR1009654B (el)	2018-08-31	2019-11-18	Φαρματεν Α.Β.Ε.Ε.	Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) *	2018-10-10	2020-04-16	Harbins Ruhr Bioscience, Inc.	Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) *	2020-05-18	2024-06-20	東和薬品株式会社	フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
US11298412B2 (en)	2020-07-16	2022-04-12	Harbins Ruhr Bioscience, Inc.	Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL7607683A (nl) *	1976-07-12	1978-01-16	Akzo Nv	Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) *	1977-05-05	1978-08-29	Chevron Research Company	1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en)	1983-10-25	1985-12-17	Phillips Petroleum Company	Metal working lubricant
US5112616A (en) *	1988-11-30	1992-05-12	Schering Corporation	Fast dissolving buccal tablet
JP2841857B2 (ja) *	1990-11-29	1998-12-24	田辺製薬株式会社	長期間安定な経口用医薬製剤
DK0627406T3 (da)	1992-10-21	1999-07-12	Taito Co	2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler
DK0778263T3 (da)	1994-08-22	2002-04-22	Mitsubishi Pharma Corp	Benzenforbindelser og farmaceutisk anvendelse af disse
US6121329A (en)	1995-12-28	2000-09-19	Yoshitomi Pharmaceutical Industries, Ltd.	Topical administration of 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol
JP2002241272A (ja)	1996-07-18	2002-08-28	Mitsubishi Pharma Corp	医薬処方組成物
JPH11209277A (ja) *	1998-01-19	1999-08-03	Yoshitomi Pharmaceut Ind Ltd	医薬組成物
US6476004B1 (en) *	1996-07-18	2002-11-05	Mitsubishi Pharma Corporation	Pharmaceutical composition
GB9624038D0 (en)	1996-11-19	1997-01-08	Sandoz Ltd	Organic compounds
WO1998037875A1 (fr) *	1997-02-27	1998-09-03	Yoshitomi Pharmaceutical Industries, Ltd.	Composition medicamenteuse
IL132208A (en)	1997-04-04	2003-07-31	Mitsubishi Pharma Corp	2-aminopropane-1,3-diol derivatives and pharmaceutical compositions containing the same
JPH1180026A (ja) *	1997-09-02	1999-03-23	Yoshitomi Pharmaceut Ind Ltd	新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja)	1998-04-01	2004-07-21	花王株式会社	スフィンゴ糖脂質の製造法
JP4627356B2 (ja) *	1999-06-30	2011-02-09	松森　　昭	ウイルス性心筋炎の予防または治療薬剤
KR20020027463A (ko) *	1999-07-12	2002-04-13	우에노 도시오	스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
MXPA03000397A (es)	2000-07-13	2003-05-27	Sankyo Co	Derivados de aminoalcohol.
CA2421893A1 (fr) *	2000-08-31	2002-03-07	Merck And Co., Inc.	Derives de phosphates utilises en tant qu'agents immuno-regulateurs
US6953332B1 (en)	2000-11-28	2005-10-11	St. Jude Medical, Inc.	Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
US7326801B2 (en)	2001-03-26	2008-02-05	Novartis Ag	2-amino-propanol derivatives
US7521192B2 (en) *	2001-04-18	2009-04-21	Rigel Pharmaceuticals, Inc.	EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja)	2001-04-20	2002-10-31	Sankyo Co Ltd	ベンゾチオフェン誘導体
WO2003020313A1 (fr)	2001-09-04	2003-03-13	Ono Pharmaceutical Co., Ltd.	Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate
DE60235900D1 (de)	2001-09-27	2010-05-20	Kyorin Seiyaku Kk	Osuppressivum
PT1431284E (pt)	2001-09-27	2008-01-21	Kyorin Seiyaku Kk	Derivado de sulfureto de diarilo, um seu sal de adição e imunossupressor
CA2473740A1 (fr)	2002-01-18	2003-07-31	David Solow-Cordero	Procedes pour traiter des pathologies associees a un recepteur d'edg
DE60330047D1 (en)	2002-01-18	2009-12-24	Merck & Co Inc	"n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten"
CA2472680A1 (fr)	2002-01-18	2003-07-31	Merck & Co., Inc.	Antagonistes selectifs du recepteur s1p1/edg1
EP1470137B1 (fr)	2002-01-18	2009-09-02	Merck & Co., Inc.	Agonistes du recepteur edg
PT1772145E (pt) *	2004-07-16	2011-05-27	Kyorin Seiyaku Kk	Processo de utiliza??o eficaz de um medicamento e processo respeitante ? preven??o de efeitos secund?rios

2004
- 2004-04-06 EP EP10186307A patent/EP2319502A1/fr not_active Withdrawn
- 2004-04-06 ES ES04725895T patent/ES2320767T3/es not_active Expired - Lifetime
- 2004-04-06 US US10/552,005 patent/US20060275357A1/en not_active Abandoned
- 2004-04-06 FR FR0450692A patent/FR2854073B1/fr not_active Expired - Lifetime
- 2004-04-06 EP EP04725895A patent/EP1613288B1/fr not_active Expired - Lifetime
- 2004-04-06 ES ES200400852A patent/ES2228282B1/es not_active Expired - Fee Related
- 2004-04-06 PL PL10184951.1T patent/PL2316431T3/pl unknown
- 2004-04-06 NZ NZ592339A patent/NZ592339A/xx not_active IP Right Cessation
- 2004-04-06 HU HUE10184951A patent/HUE028247T2/en unknown
- 2004-04-06 EP EP08161161A patent/EP2008650A3/fr not_active Withdrawn
- 2004-04-06 KR KR1020127019448A patent/KR101367574B1/ko active IP Right Grant
- 2004-04-06 JP JP2004111761A patent/JP5495467B2/ja not_active Expired - Lifetime
- 2004-04-06 AT AT04725895T patent/ATE414508T1/de active
- 2004-04-06 KR KR1020057019066A patent/KR20050121712A/ko not_active Application Discontinuation
- 2004-04-06 PE PE2004000355A patent/PE20050396A1/es not_active Application Discontinuation
- 2004-04-06 PE PE2015000303A patent/PE20150676A1/es not_active Application Discontinuation
- 2004-04-06 NZ NZ542622A patent/NZ542622A/xx not_active IP Right Cessation
- 2004-04-06 SI SI200432283T patent/SI2316431T1/sl unknown
- 2004-04-06 RU RU2005134173/15A patent/RU2358716C2/ru not_active IP Right Cessation
- 2004-04-06 CA CA2707750A patent/CA2707750A1/fr not_active Abandoned
- 2004-04-06 IT IT000682A patent/ITMI20040682A1/it unknown
- 2004-04-06 PE PE2008001684A patent/PE20090743A1/es not_active Application Discontinuation
- 2004-04-06 BR BRPI0409250A patent/BRPI0409250B8/pt active IP Right Grant
- 2004-04-06 AU AU2004228929A patent/AU2004228929B2/en active Active
- 2004-04-06 PL PL04725895T patent/PL1613288T3/pl unknown
- 2004-04-06 DE DE201112100047 patent/DE122011100047I1/de active Pending
- 2004-04-06 CN CN2010101213007A patent/CN101797241B/zh not_active Expired - Lifetime
- 2004-04-06 SG SG2008040545A patent/SG175449A1/en unknown
- 2004-04-06 DK DK10184951.1T patent/DK2316431T3/en active
- 2004-04-06 EP EP10184951.1A patent/EP2316431B1/fr not_active Revoked
- 2004-04-06 CN CN2004800092370A patent/CN1767819B/zh not_active Expired - Lifetime
- 2004-04-06 CA CA2521325A patent/CA2521325C/fr not_active Expired - Lifetime
- 2004-04-06 PT PT04725895T patent/PT1613288E/pt unknown
- 2004-04-06 ES ES10184951.1T patent/ES2556947T3/es not_active Expired - Lifetime
- 2004-04-06 SI SI200431037T patent/SI1613288T1/sl unknown
- 2004-04-06 DE DE102004016947A patent/DE102004016947A1/de active Pending
- 2004-04-06 NZ NZ586280A patent/NZ586280A/en not_active IP Right Cessation
- 2004-04-06 DE DE202004021680U patent/DE202004021680U1/de not_active Expired - Lifetime
- 2004-04-06 EP EP14163450.1A patent/EP2769713A1/fr not_active Withdrawn
- 2004-04-06 DE DE602004017847T patent/DE602004017847D1/de not_active Expired - Lifetime
- 2004-04-06 GB GB0407819A patent/GB2400318B/en not_active Expired - Lifetime
- 2004-04-06 MX MXPA05010860A patent/MXPA05010860A/es active IP Right Grant
- 2004-04-06 GR GR20040100121A patent/GR1005052B/el unknown
- 2004-04-06 PE PE2013000382A patent/PE20131352A1/es active IP Right Grant
- 2004-04-06 AR ARP040101162A patent/AR043987A1/es not_active Application Discontinuation
- 2004-04-06 AT ATA606/2004A patent/AT501681B1/de not_active IP Right Cessation
- 2004-04-06 KR KR1020107029859A patent/KR20110005320A/ko not_active Application Discontinuation
- 2004-04-06 WO PCT/EP2004/003656 patent/WO2004089341A1/fr active Application Filing
- 2004-04-06 DK DK04725895T patent/DK1613288T3/da active
- 2004-04-06 PE PE2012002027A patent/PE20130200A1/es not_active Application Discontinuation
- 2004-04-07 TW TW093109631A patent/TWI332847B/zh active
- 2004-04-07 MY MYPI20041275A patent/MY141249A/en unknown
- 2004-04-07 BE BE2004/0180A patent/BE1015972A5/fr not_active IP Right Cessation
- 2004-04-07 CL CL200400745A patent/CL2004000745A1/es unknown
2005
- 2005-03-31 HK HK05102715A patent/HK1071685A1/xx not_active IP Right Cessation
- 2005-09-14 ZA ZA200507394A patent/ZA200507394B/en unknown
- 2005-09-15 IL IL170888A patent/IL170888A/en active IP Right Grant
- 2005-10-06 HR HR20050886A patent/HRP20050886B1/xx not_active IP Right Cessation
- 2005-10-07 EC EC2005006090A patent/ECSP056090A/es unknown
- 2005-10-07 TN TNP2005000256A patent/TNSN05256A1/en unknown
- 2005-10-19 MA MA28560A patent/MA27729A1/fr unknown
- 2005-11-01 IS IS8114A patent/IS2682B/is unknown
- 2005-11-07 NO NO20055231A patent/NO329332B1/no active Protection Beyond IP Right Term
2006
- 2006-07-06 HK HK06107621.6A patent/HK1091114A1/xx not_active IP Right Cessation
2008
- 2008-05-08 AT AT0074408A patent/AT504853A2/de not_active Application Discontinuation
- 2008-08-11 US US12/189,323 patent/US8324283B2/en not_active Expired - Fee Related
- 2008-08-13 US US12/191,098 patent/US20090203798A1/en not_active Abandoned
2009
- 2009-02-17 RU RU2009105403/15A patent/RU2009105403A/ru not_active Application Discontinuation
- 2009-02-19 CY CY20091100192T patent/CY1110260T1/el unknown
- 2009-03-12 IL IL197578A patent/IL197578A/en active IP Right Grant
2010
- 2010-02-18 NO NO20100250A patent/NO334116B1/no unknown
- 2010-02-25 IS IS8885A patent/IS8885A/is unknown
- 2010-08-25 JP JP2010188835A patent/JP5543298B2/ja not_active Expired - Lifetime
- 2010-10-26 AR ARP100103930A patent/AR078781A2/es not_active Application Discontinuation
- 2010-10-26 AR ARP100103931A patent/AR078782A2/es not_active Application Discontinuation
- 2010-11-08 HR HR20100600A patent/HRP20100600A2/hr not_active Application Discontinuation
- 2010-11-08 HR HRP20100601AA patent/HRP20100601B1/hr not_active IP Right Cessation
- 2010-11-17 RU RU2010146697/15A patent/RU2475236C2/ru active
- 2010-11-18 RU RU2010147000/15A patent/RU2475237C2/ru active
2011
- 2011-01-10 US US12/987,726 patent/US20110105620A1/en not_active Abandoned
- 2011-03-01 CL CL2011000450A patent/CL2011000450A1/es unknown
- 2011-09-06 HU HUS1100016C patent/HUS1100016I1/hu unknown
- 2011-09-08 FR FR11C0036C patent/FR11C0036I2/fr active Active
- 2011-09-08 CY CY2011013C patent/CY2011013I1/el unknown
- 2011-09-08 LU LU91867C patent/LU91867I2/fr unknown
- 2011-09-08 BE BE2011C030C patent/BE2011C030I2/fr unknown
- 2011-09-08 NO NO2011016C patent/NO2011016I2/no unknown
- 2011-09-21 HK HK11109933.8A patent/HK1155647A1/xx not_active IP Right Cessation
2012
- 2012-11-15 RU RU2012148593/15A patent/RU2012148593A/ru not_active Application Discontinuation
- 2012-12-20 US US13/721,278 patent/US20130108675A1/en not_active Abandoned
2013
- 2013-04-23 JP JP2013090602A patent/JP2013177404A/ja active Pending
- 2013-09-16 US US14/027,943 patent/US20140011885A1/en not_active Abandoned
- 2013-09-26 NO NO20131287A patent/NO335120B1/no unknown
2014
- 2014-05-23 US US14/285,808 patent/US20140255497A1/en not_active Abandoned
2015
- 2015-10-12 IL IL242037A patent/IL242037A0/en unknown
- 2015-12-29 CY CY20151101194T patent/CY1117071T1/el unknown
2017
- 2017-06-27 US US15/634,579 patent/US20170290787A1/en not_active Abandoned
2019
- 2019-02-13 US US16/274,357 patent/US20190175527A1/en not_active Abandoned
2020
- 2020-04-03 US US16/839,703 patent/US20200237690A1/en not_active Abandoned
2021
- 2021-10-14 US US17/501,173 patent/US20220031609A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2316431B1 (fr)	2015-09-30
BRPI0409250B8 (pt)	2022-01-18
EP2008650A2 (fr)	2008-12-31
US20220031609A1 (en)	2022-02-03
KR20110005320A (ko)	2011-01-17
CA2521325C (fr)	2010-09-14
WO2004089341A1 (fr)	2004-10-21
HRP20050886A2 (en)	2006-11-30
FR11C0036I1 (fr)	2011-10-14
GB2400318B (en)	2005-08-10
MA27729A1 (fr)	2006-01-02
FR2854073A1 (fr)	2004-10-29
GB0407819D0 (en)	2004-05-12
CY2011013I2 (el)	2014-04-09
EP1613288A1 (fr)	2006-01-11
JP2011006461A (ja)	2011-01-13
AU2004228929A1 (en)	2004-10-21
RU2475236C2 (ru)	2013-02-20
NO2011016I2 (no)	2012-08-27
RU2475237C2 (ru)	2013-02-20
US20190175527A1 (en)	2019-06-13
PE20090743A1 (es)	2009-07-17
BE2011C030I2 (fr)	2023-03-07
PE20150676A1 (es)	2015-05-17
NO329332B1 (no)	2010-09-27
FR2854073B1 (fr)	2008-03-14
RU2012148593A (ru)	2014-05-20
TNSN05256A1 (en)	2007-07-10
AU2004228929B2 (en)	2008-02-07
NO20055231L (no)	2006-01-09
PL2316431T3 (pl)	2016-09-30
CY1110260T1 (el)	2014-04-09
PE20050396A1 (es)	2005-07-05
RU2358716C2 (ru)	2009-06-20
DK2316431T3 (en)	2016-01-11
GR1005052B (el)	2005-11-30
JP5495467B2 (ja)	2014-05-21
GB2400318A (en)	2004-10-13
MY141249A (en)	2010-03-31
CN101797241B (zh)	2013-03-27
ES2228282B1 (es)	2006-02-16
DE202004021680U1 (de)	2010-04-22
PE20131352A1 (es)	2013-11-14
CL2004000745A1 (es)	2005-02-11
US20140011885A1 (en)	2014-01-09
IL197578A (en)	2015-10-29
US20170290787A1 (en)	2017-10-12
CA2707750A1 (fr)	2004-10-21
JP2013177404A (ja)	2013-09-09
AR078781A2 (es)	2011-11-30
NO335120B1 (no)	2014-09-22
NO2011016I1 (no)	2011-09-19
HK1155647A1 (en)	2012-05-25
CY1117071T1 (el)	2017-04-05
NO334116B1 (no)	2013-12-16
MXPA05010860A (es)	2006-05-25
ITMI20040682A1 (it)	2004-07-06
HRP20100600A2 (hr)	2011-03-31
HK1071685A1 (en)	2005-07-29
HRP20100601B1 (hr)	2016-12-02
ES2320767T3 (es)	2009-05-28
IL197578A0 (en)	2011-07-31
IS8885A (is)	2010-02-25
KR20050121712A (ko)	2005-12-27
IL242037A0 (en)	2015-11-30
HUE028247T2 (en)	2016-12-28
HRP20100601A2 (hr)	2011-03-31
RU2010146697A (ru)	2012-05-27
EP1613288B1 (fr)	2008-11-19
ES2228282A1 (es)	2005-04-01
US20110105620A1 (en)	2011-05-05
BRPI0409250A (pt)	2006-03-28
ECSP056090A (es)	2006-03-01
SI2316431T1 (sl)	2016-04-29
AT504853A2 (de)	2008-08-15
CN101797241A (zh)	2010-08-11
IS2682B (is)	2010-10-15
EP2319502A1 (fr)	2011-05-11
PL1613288T3 (pl)	2009-07-31
US20140255497A1 (en)	2014-09-11
AT501681B1 (de)	2012-04-15
TW200503784A (en)	2005-02-01
NZ586280A (en)	2011-12-22
CA2521325A1 (fr)	2004-10-21
US20090203798A1 (en)	2009-08-13
BRPI0409250B1 (pt)	2017-07-11
NO20055231D0 (no)	2005-11-07
BE1015972A5 (fr)	2005-12-06
CL2011000450A1 (es)	2011-11-25
ZA200507394B (en)	2007-03-28
KR20120101148A (ko)	2012-09-12
GR20040100121A (el)	2004-12-17
EP2769713A1 (fr)	2014-08-27
US20080311188A1 (en)	2008-12-18
NZ592339A (en)	2012-09-28
TWI332847B (en)	2010-11-11
JP5543298B2 (ja)	2014-07-09
LU91867I2 (fr)	2011-11-08
DE122011100047I1 (de)	2011-12-15
EP2316431A1 (fr)	2011-05-04
DE102004016947A1 (de)	2004-10-21
PE20130200A1 (es)	2013-03-09
US20130108675A1 (en)	2013-05-02
US20200237690A1 (en)	2020-07-30
SI1613288T1 (sl)	2009-04-30
HUS1100016I1 (hu)	2016-08-29
CN1767819B (zh)	2010-07-28
EP2008650A3 (fr)	2011-04-27
SG175449A1 (en)	2011-11-28
HRP20050886B1 (en)	2011-01-31
HK1091114A1 (en)	2007-01-12
RU2010147000A (ru)	2012-08-10
LU91867I9 (fr)	2019-01-03
KR101367574B1 (ko)	2014-02-25
RU2009105403A (ru)	2010-08-27
IE20040246A1 (en)	2004-12-15
PT1613288E (pt)	2009-02-25
AR078782A2 (es)	2011-11-30
AR043987A1 (es)	2005-08-17
IS8114A (is)	2005-11-01
JP2004307506A (ja)	2004-11-04
ATE414508T1 (de)	2008-12-15
DK1613288T3 (da)	2009-03-23
CY2011013I1 (el)	2014-04-09
NO20100250L (no)	2006-01-09
IL170888A (en)	2010-06-16
NZ542622A (en)	2009-01-31
NO20131287L (no)	2006-01-09
DE602004017847D1 (de)	2009-01-02
CN1767819A (zh)	2006-05-03
US20060275357A1 (en)	2006-12-07
AT501681A1 (de)	2006-10-15
ES2556947T3 (es)	2016-01-21
RU2005134173A (ru)	2006-09-10
US8324283B2 (en)	2012-12-04

Publication	Publication Date	Title
FR11C0036I2 (fr)	2023-12-29	Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre
DZ3484A1 (fr)	2002-06-20	Compositions pharmaceutiques comprenant un agoniste des recepteurs nmda
ZA200801575B (en)	2008-12-31	Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
ATE354362T1 (de)	2007-03-15	Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
EP1648474A4 (fr)	2009-03-25	Methodes et compositions pharmaceutiques pour cicatriser des lesions
EP1900368A4 (fr)	2009-08-12	Comprimé contenant un ingrédient actif à peine soluble
MA28527B1 (fr)	2007-04-03	Formulations orales contenant licarbazepine
EP1830831A4 (fr)	2010-12-15	Formulations pharmaceutiques contenant des sels de gallium
EA200601015A1 (ru)	2006-10-27	Пероральные композиции дезоксипеганина и их применение
ITMI20061741A1 (it)	2008-03-13	Composizioni farmaceutiche per la somministrazione orale di sostanze proteiche
DE112004002737D2 (de)	2006-11-23	Lösungsmittel für biogene pharmazeutische Wirkstoffe
EP1626961A4 (fr)	2008-07-16	Nouveaux composes 2-oxo-heterocycliques et compositions pharmaceutiques contenant ces composes
TH72202B (th)	2019-10-25	องค์ประกอบทางเภสัชกรรมชนิดแข็งประกอบด้วย s1p รีเซพเตอร์แอกโกนิสท์และชูการ์แอลกอฮอล์
TH70717A (th)	2005-09-29	องค์ประกอบทางเภสัชกรรมชนิดแข็งประกอบด้วย s1p รีเซพเตอร์แอกโกนิสท์และชูการ์แอลกอฮอล์
TH2523A3 (th)	2006-04-24	ผลิตภัณฑ์ น้ำยาบ้วนปากเพื่อลดความอยากอาหาร
TH2523C3 (th)	2006-04-24	ผลิตภัณฑ์ น้ำยาบ้วนปากเพื่อลดความอยากอาหาร
TH91424A (th)	2008-09-19	วิธีการและสารผสมสำหรับผลิตภัณฑ์ทางเภสัชกรรม
ITMI20041849A1 (it)	2004-12-29	Formulazioni farmaceutiche per l'integrazione alimentare di soggetti anoressici